-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UZPbUPTibjLsVUodUTl/by4J+DfBEzZ+ZY+GVf4sf03cLZ5FF2TnEZ5B21N/0dAS rOqmgH+CORsUYxlxccq8cA== 0001104659-03-011377.txt : 20030530 0001104659-03-011377.hdr.sgml : 20030530 20030530114259 ACCESSION NUMBER: 0001104659-03-011377 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030529 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30975 FILM NUMBER: 03724800 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 8-K 1 j1663_8k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

May 29, 2003

 

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

 

000-30975

(State of Formation)

 

(Commission File Number)

 

 

 

911789357

(IRS Employer Identification Number)

 

 

 

12325 Emmet Street
Omaha, NE

 

68164

(Address of principal executive offices)

 

(Zip Code)

 

 

 

(402) 452-5400

(Registrants’ telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

 

 

Item 5.  Other Events and Regulation FD Disclosure.

 

On May 29, 2003, the Company issued a press release announcing changes in management responsibilities including the appointment of Michael J. Draper as its Chief Financial Officer.  The Company is attaching the press release as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.  Financial Statements and Exhibits.

 

(c)  Exhibits

 

99.1                           Press Release, dated May 29, 2003, announcing changes in management responsibilities including the appointment of Michael J. Draper as Chief Financial Officer of Transgenomic, Inc. (the “Company”).

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

TRANSGENOMIC, INC.

 

 

 

 

 

By

/s/ Michael J. Draper

 

 

 

Michael J. Draper, Chief Financial Officer

 

 

 

 

May 29, 2003

 

 

3

 EX-99.1 3 j1663_ex99d1.htm EX-99.1

Exhibit 99.1

 

Thursday, May 29, 2003

 

 

COMPANY PRESS RELEASE

 

TRANSGENOMIC ANNOUNCES CHANGES IN MANAGEMENT RESPONSIBILITIES IN LINE WITH EVOLVING BUSINESS SEGMENT FOCUS

 

OMAHA, Neb., May 29 / PRNewswire / — Transgenomic, Inc. (Nasdaq: TBIO) announced today several senior management initiatives aimed at further supporting its evolving business segmentation. This segmented approach to operations results directly from the Company’s ongoing efforts to diversify its revenue streams.

 

Michael Draper has been appointed to the role of chief financial officer, succeeding interim CFO William Rasmussen, who remains with the Company in a strategic planning capacity as well as retaining responsibility for human resources and administration. Mr. Draper joined Transgenomic in April 2000 and assumed the position of controller shortly thereafter. Prior to joining Transgenomic, Mr. Draper was vice president of accounting and finance for a privately held company. He also spent eight years with the audit group of Deloitte & Touche.

 

Mitchell Murphy, currently vice president, secretary and treasurer, has also assumed formal responsibility for corporate governance and regulatory compliance. Mr. Murphy has been with the Company and its predecessor companies since 1992 serving in various financial, accounting and administrative capacities.

 

The sales and marketing, and research and development functions for the Company’s biosystems segment have been consolidated. Ben Nouri, Ph.D., has assumed responsibility for marketing operations in addition to his current global sales management duties. Similarly, Mario Noyer-Weidner, Ph.D., has assumed full responsibility for all biosystems research and development. Dr. Nouri has been with the Company since 1997, while Dr. Noyer-Weidner joined in 2000.

 

In the nucleic acids segment of the Company’s business, Leo Beigelman, Ph.D., has assumed oversight of all chemistry research and development, while Dwight Muhlbradt continues to have responsibility for all business development activity. Both Dr. Beigelman and Mr. Muhlbradt joined Transgenomic in 2002.

 

John Allbery has added the responsibility for the Company’s nucleic acid synthesis operations. Mr. Allbery now manages global manufacturing operations for both business segments, as well as directing Mr. Muhlbradt’s business development activity. Mr. Allbery joined the Company in 2001. He, along with all other senior management mentioned, report directly to Collin D’Silva, CEO.

 

In commenting on the evolving management responsibilities, D’Silva said, “These management initiatives leave us well positioned to capitalize on the opportunities that lie ahead. Mike Draper’s strong financial background and his experience at Transgenomic allows for a smooth transition from Bill Rasmussen’s tenure as interim CFO. And John Allbery brings an extensive business background along with strong organizational and leadership skills to the task of managing both business segments’ manufacturing operations.” Regarding the consolidation of sales and marketing, and research and development leadership, D’Silva commented, “The managers within both of our business segments have extensive experience in various facets of the life sciences industry. That, along with their experience with Transgenomic, will enable them to effectively coordinate activities both within and between their functional areas to ensure sound, consistent management decisions.”

 

1

 

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics. Manufacturing operations include a cGMP facility for the synthesis of oligonucleotides.

 

Transgenomic’s biosystems segment offers its WAVE® Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world.

 

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company’s Web site at www.transgenomic.com.

 

Forward Looking Statement

 

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to future strengthening of the management team, and accomplishing a smooth transition from one manager to another. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release, and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

 

#  #  #  #

 

For more information contact:

 

Mitchell L. Murphy

Transgenomic, Inc.

402-452-5418

mmurphy@transgenomic.com

 

Robert J. Pogulis, Ph.D.

Transgenomic, Inc.

845-782-9617

rpogulis@transgenomic.com

 

2

 -----END PRIVACY-ENHANCED MESSAGE-----